{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Prevalence of Osteoporosis and Osteoporotic FracTure and ROle of Teriparatide in the Management of Osteoporosis (POFTO study)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
General Questions
  1. How many osteoporosis patients do you see per day? *

  2. Out of above patients, how many are present with fragility fractures in a month? *

  3. What is the male and female ratio among patients who are present with osteoporotic fractures? *

  4. What is the common age group of patients who are present with osteoporotic fractures? *
  5. According to you what are the common risk factors for osteoporotic fractures in Indian context? *
  6. Which are the most common sites for osteoporotic fractures *

  7. Which diagnostic tools are most effective in identifying osteoporosis and fracture risk? *

  8. DEXA scan to assess bone mineral density is must to do irrespective of other investigations to diagnose osteoporosis. *

  9. As per your clinical experience what are the early signs and symptoms of osteoporosis that patients should be aware of?*
  10. What is your approach in the management of osteoporotic vertebral compression fractures? *
  11. What is your approach in the management of osteoporotic fractures in young patients lesser than 50 years of age? *
  12. What is your approach in the management of non-vertebral osteoporotic fractures? *
  13. Surgical intervention is mandatory in osteoporotic fracture before proceeding for medical management? *

  14. What is your approach in the management of high-risk osteoporotic patients without prevalent fractures? *
  15. What is your approach in the management of osteoporosis in patients with chronic kidney disease? *
  16. In your clinical practice which of the following molecule is preferred as first line therapy in the prevention of osteoporotic vertebral compression fractures? *

  17. In your clinical practice which of the following molecule is preferred as first line therapy the prevention of osteoporotic non-vertebral fractures? *

  18. In your clinical practice which of the following molecule is preferred as first line therapy in management of high-risk osteoporotic patients without fractures? *

  19. Drug holiday can be considered to reduce the incidence of adverse events associated with anti-resorptive therapy in patients who have high risk of fragility fracture. *

  20. Drug holiday can be considered to reduce the incidence of adverse events associated with anti-resorptive therapy in patients who have low-moderate risk of fragility fracture. *

  21. In which of the following osteoporotic fractures there are high chances of positive therapeutic outcome as per your clinical experience? (Multiple options can be selected) *

  22. What is your approach in the usage of vitamin D and calcium in the management of osteoporosis? (Multiple options can be selected) *

  23. As per your clinical experience how does addition of calcium and vitamin D help in osteoporotic fracture management? *
  24. What is the duration of teriparatide therapy to prevent osteoporotic fracture or recurrence of fracture in your clinical practice? *

  25. What are the common causes of discontinuation of teriparatide therapy before prescribed duration? (Multiple options can be selected) *

  26. What proportion of patients comes with recurrent fractures after completing teriparatide therapy in your clinical practice? *

  27. Do you prefer combination therapy of teriparatide with antiresorptive agent to prevent osteoporotic fragility fracture? *

  28. If answer to above question is yes which of the following combination therapy do you prefer? (Multiple options can be selected)

  29. Do you prefer sequential therapies with teriparatide to prevent osteoporotic fragility fracture? *

  30. If answer to above question is yes, which of the following sequential therapy do you prefer? (Multiple options can be selected)

  31. What are the treatment goals when you prescribe teriparatide for the management of osteoporosis? *
  32. How do you monitor the improvement with teriparatide in patients with osteoporosis and osteoporotic fractures? *
  33. Do you use bone markers like P1NP and CTX to monitor the improvement with teriparatide? *

  34. Bone marker assessment like P1 NP can help to improve patient adherence to anti- osteoporotic treatment. *

  35. What should be the ideal rehabilitation plan for patients with osteoporotic fractures after surgical and medical interventions? *
  36. What is the frequency of follow-up in your clinical practice after giving anti-osteoporotic therapy? *
  37. Are you aware that teriparatide can be prescribed beyond 2 years if patient with osteoporosis is at high risk for developing fracture? *

  38. As per your clinical experience what are the ways to increase the awareness about teriparatide use for recommended duration to achieve optimum therapeutic outcomes? *
  39. How can patient of osteoporosis prevent fragility fractures? (Multiple options can be selected) *

  40. What initiatives to be taken to increase awareness about osteoporosis and prevent osteoporotic fracture among general population? *